OTCQB: OXIS

Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline

About

OXIS International, Inc., develops and commercializes innovative immunotherapeutic for the treatment of cancer and other unmet medical needs.

learn more
About
Technology

Technology

Antibody-drug conjugates are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer.

learn more

Latest News

GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned Merger
Aug 21, 2017 • 12:00 EDT | Read More

GT Biopharma, Inc. (Oxis) Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo
Aug 7, 2017 • 8:00 EDT | Read More

Investors

OXIS International Inc. OTCQB: OXIS
Loading... Change
Loading... Volume
Loading... 52 Week Range